Senti Biosciences (NASDAQ:SNTI – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, Zacks reports.
Senti Biosciences Stock Performance
Shares of SNTI traded down $0.11 during trading hours on Thursday, hitting $3.51. The stock had a trading volume of 16,781 shares, compared to its average volume of 781,284. The company’s fifty day simple moving average is $3.95 and its 200 day simple moving average is $3.44. Senti Biosciences has a 12-month low of $1.52 and a 12-month high of $16.94. The firm has a market cap of $16.95 million, a P/E ratio of -0.23 and a beta of 2.52.
Analysts Set New Price Targets
Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Senti Biosciences in a research report on Monday, December 2nd.
Senti Biosciences Company Profile
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Featured Articles
- Five stocks we like better than Senti Biosciences
- Growth Stocks: What They Are, What They Are Not
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- What Are the U.K. Market Holidays? How to Invest and Trade
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.